239 related articles for article (PubMed ID: 34788412)
21. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
22. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
[TBL] [Abstract][Full Text] [Related]
23. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.
Anolik JH; Campbell D; Felgar RE; Young F; Sanz I; Rosenblatt J; Looney RJ
Arthritis Rheum; 2003 Feb; 48(2):455-9. PubMed ID: 12571855
[TBL] [Abstract][Full Text] [Related]
24. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
25. A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE.
van Dam LS; Osmani Z; Kamerling SWA; Kraaij T; Bakker JA; Scherer HU; Rabelink TJ; Voll RE; Alexander T; Isenberg DA; van Kooten C; Teng YKO
Rheumatology (Oxford); 2020 Oct; 59(10):2734-2745. PubMed ID: 31951278
[TBL] [Abstract][Full Text] [Related]
26. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
[TBL] [Abstract][Full Text] [Related]
27. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
28. B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab.
Parodis I; Gomez A; Lindblom J; Chow JW; Sjöwall C; Sciascia S; Gatto M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430417
[TBL] [Abstract][Full Text] [Related]
29. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20).
Eisenberg R
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):345-50. PubMed ID: 17214580
[TBL] [Abstract][Full Text] [Related]
30. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
[TBL] [Abstract][Full Text] [Related]
32. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
Reddy V; Jayne D; Close D; Isenberg D
Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295
[TBL] [Abstract][Full Text] [Related]
33. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
[TBL] [Abstract][Full Text] [Related]
34. B cell depletion and inhibition in systemic lupus erythematosus.
Krustev E; Clarke AE; Barber MRW
Expert Rev Clin Immunol; 2023 Jan; 19(1):55-70. PubMed ID: 36342225
[TBL] [Abstract][Full Text] [Related]
35. Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: A systematic review update.
Rodziewicz M; Mendoza-Pinto C; Dyball S; Munguía-Realpozo P; Parker B; Bruce IN
Semin Arthritis Rheum; 2024 Apr; 65():152346. PubMed ID: 38185077
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
[TBL] [Abstract][Full Text] [Related]
37. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
Tanaka Y
Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
[TBL] [Abstract][Full Text] [Related]
38. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
Looney RJ; Anolik JH; Campbell D; Felgar RE; Young F; Arend LJ; Sloand JA; Rosenblatt J; Sanz I
Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
[TBL] [Abstract][Full Text] [Related]
39. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.
Hui-Yuen JS; Nguyen SC; Askanase AD
Lupus; 2016 Sep; 25(10):1086-96. PubMed ID: 27497253
[TBL] [Abstract][Full Text] [Related]
40. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]